Toshiaki Saida
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Toshiaki Saida has a total of 103 co-authors. Here are the top co-authors by number of shared publications:
- Hisashi Uhara
Department of Dermatology, Shinshu University School of Medicine, Matsumoto, Japan
15 shared publications - Hiroshi Koga
Kitatoda Alps Dermatology Clinic Toda Japan
6 shared publications Shigeo Kawachi
5 shared publicationsHisashi Uhara
Department of Dermatology, Sapporo Medical University School of Medicine, Sapporo, Japan
4 shared publicationsHiroshi Koga
Department of Dermatology, Shinshu University School of Medicine, Matsumoto, Japan
3 shared publications- Koichi Hayashi
Department of Dermatology, Shinshu University School of Medicine, Matsumoto, Japan
2 shared publications
Latest Publications
- Open Access
- 1 July 2022
- Published by Mattioli1885 in Dermatology Practical & Conceptual
- Vol. 12 (3) , e2022123
Dermoscopy for acral melanocytic lesions: Revision of the 3-step algorithm and refined definition of the regular and irregular fibrillar pattern
Citation: Saida T, Koga H, Uhara H. Dermoscopy for acral melanocytic lesions: Revision of the 3-step algorithm and refined definition of the regular and irregular fibrillar pattern. Dermatol Pract Concept. 2022;12(03):e2022123. DOI: https://doi.org/10.5826/dpc.1203a123 Accepted: October 26, 2021; Published: July 2022 Copyright: ©2022 Saida et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License (BY-NC-4.0), https://creativecommons.org/licenses/by-nc/4.0/, which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original authors and source are credited. Funding: None. Competing interests: None. Authorship: All authors have contributed significantly to this publication. Corresponding author: Toshiaki Saida, MD, PhD, Shinshu University, Matsumoto, Kamiochiai 7-7-40-220, Chuo-ku, Saitama 338-0001, Japan. E-mail: tosaida@xb4.so-net.ne.jp Keywords : dermoscopy, early acral melanoma, acral nevus, 3-step algorithm, regular and irregular fibrillar pattern This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
- 1 July 2022
- Published by Mattioli1885 in Dermatology Practical & Conceptual
- Vol. 12 (3) , e2022123
Open AccessDermoscopy for acral melanocytic lesions: Revision of the 3-step algorithm and refined definition of the regular and irregular fibrillar pattern
Citation: Saida T, Koga H, Uhara H. Dermoscopy for acral melanocytic lesions: Revision of the 3-step algorithm and refined definition of the regular and irregular fibrillar pattern. Dermatol Pract Concept. 2022;12(03):e2022123. DOI: https://doi.org/10.5826/dpc.1203a123 Accepted: October 26, 2021; Published: July 2022 Copyright: ©2022 Saida et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License (BY-NC-4.0), https://creativecommons.org/licenses/by-nc/4.0/, which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original authors and source are credited. Funding: None. Competing interests: None. Authorship: All authors have contributed significantly to this publication. Corresponding author: Toshiaki Saida, MD, PhD, Shinshu University, Matsumoto, Kamiochiai 7-7-40-220, Chuo-ku, Saitama 338-0001, Japan. E-mail: tosaida@xb4.so-net.ne.jp Keywords : dermoscopy, early acral melanoma, acral nevus, 3-step algorithm, regular and irregular fibrillar pattern This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
- 8 August 2019
- Published by Springer Nature
- p. 411-438
Acral Melanoma
- Open Access
- 15 May 2019
- Published by Wiley in The Journal of Dermatology
- Vol. 46 (7) , 557-563
Long‐term efficacy and safety of bexarotene for Japanese patients with cutaneous T‐cell lymphoma: The results of a phase 2 study (B‐1201)
The present study (B‐1201 clinical trial) was conducted as a multicenter, open‐label, single‐arm phase II study to evaluate the long‐term safety, tolerability and efficacy of bexarotene. This study enrolled 10 Japanese adults aged more than 20 years with cutaneous T‐cell lymphoma (CTCL) who completed the 24‐week study period of the B‐1101 trial. The objective response rate (ORR) was 53.8% (95% confidence interval, 25.1–80.8). In the early stage (IB), the ORR was 60% (3/5 cases). In the advanced stage (IIB and IIIA), the ORR was 57.1% (4/7 cases). The median time to response was 58 days (range, 27–168). The median treatment duration was 380 days (range, 33–1674). The median duration of response (DOR) could not be reached during the study period. The longest DOR reached 1618 days at the end of the B‐1201 trial. Nine patients (56.3%) in the full analysis set (FAS) population experienced dose reduction of bexarotene. Common drug‐related adverse events in the FAS population included hypothyroidism (93.8%), hypertriglyceridemia (81.3%), hypercholesterolemia (81.3%), leukopenia (68.8%) and neutropenia (56.3%). Dose‐limiting toxicity (DLT) was present in five (38.5%) of the 13 patients in the 300 mg/m2 cohort. Of the five patients, four developed grade 3 neutropenia and one developed grade 4 hypertriglyceridemia. All DLT cases recovered after the discontinuation of bexarotene. None of the five patients discontinued this trial because of DLT. The B‐1201 trial shows the long‐term safety of oral bexarotene for Japanese patients with CTCL, despite frequent dose reduction.
- 15 May 2019
- Published by Wiley in The Journal of Dermatology
- Vol. 46 (7) , 557-563
Open AccessLong‐term efficacy and safety of bexarotene for Japanese patients with cutaneous T‐cell lymphoma: The results of a phase 2 study (B‐1201)
The present study (B‐1201 clinical trial) was conducted as a multicenter, open‐label, single‐arm phase II study to evaluate the long‐term safety, tolerability and efficacy of bexarotene. This study enrolled 10 Japanese adults aged more than 20 years with cutaneous T‐cell lymphoma (CTCL) who completed the 24‐week study period of the B‐1101 trial. The objective response rate (ORR) was 53.8% (95% confidence interval, 25.1–80.8). In the early stage (IB), the ORR was 60% (3/5 cases). In the advanced stage (IIB and IIIA), the ORR was 57.1% (4/7 cases). The median time to response was 58 days (range, 27–168). The median treatment duration was 380 days (range, 33–1674). The median duration of response (DOR) could not be reached during the study period. The longest DOR reached 1618 days at the end of the B‐1201 trial. Nine patients (56.3%) in the full analysis set (FAS) population experienced dose reduction of bexarotene. Common drug‐related adverse events in the FAS population included hypothyroidism (93.8%), hypertriglyceridemia (81.3%), hypercholesterolemia (81.3%), leukopenia (68.8%) and neutropenia (56.3%). Dose‐limiting toxicity (DLT) was present in five (38.5%) of the 13 patients in the 300 mg/m2 cohort. Of the five patients, four developed grade 3 neutropenia and one developed grade 4 hypertriglyceridemia. All DLT cases recovered after the discontinuation of bexarotene. None of the five patients discontinued this trial because of DLT. The B‐1201 trial shows the long‐term safety of oral bexarotene for Japanese patients with CTCL, despite frequent dose reduction.
- 11 January 2019
- Published by Wiley in The Journal of Dermatology
- Vol. 46 (2) , 80-94
Histogenesis of cutaneous malignant melanoma: The vast majority do not develop from melanocytic nevus but arise de novo as melanoma in situ
It has been considered that most cutaneous malignant melanomas arise from pre‐existing melanocytic nevus. Many clinical and histopathological studies seem to support this concept. Dysplastic nevus originally proposed by Clark's group is a key entity of the intermediate lesion between benign nevus and melanoma. The latest edition of the WHO Classification of Skin Tumours (2018) has excluded Clark nevus (dysplastic nevus of mild atypia) from dysplastic nevus, the latter being now classified into the low‐ and high‐grade by the degrees of nuclear atypia. The World Health Organization classification regards dysplastic nevus of both grades as the intermediate lesion between common acquired nevus and the radial growth‐phase melanoma. An extensive genetic study recently performed by Bastian's group indicated the existence of intermediate lesions between nevus and melanoma. In spite of these findings, some investigators doubt the concept of the intermediate lesions including dysplastic nevus and insist that the majority of melanomas arise de novo as melanoma in situ, not in association with a preceding nevus. The concept of de novo genesis of melanoma may be supported by a recent meta‐analysis study revealing that 71% of melanomas likely arose de novo and 29% from pre‐existing nevus. In this review article, from the viewpoint of de novo genesis of melanoma, the author critically discusses the relevant findings of melanoma genesis and proposes a new framework to interpret the morphological and genetic data alternatively. Clarification of the oncogenic process of melanoma has great impact not only on clinical dermatology but also on basic oncology.
- 11 January 2019
- Published by Wiley in The Journal of Dermatology
- Vol. 46 (2) , 80-94
Histogenesis of cutaneous malignant melanoma: The vast majority do not develop from melanocytic nevus but arise de novo as melanoma in situ
It has been considered that most cutaneous malignant melanomas arise from pre‐existing melanocytic nevus. Many clinical and histopathological studies seem to support this concept. Dysplastic nevus originally proposed by Clark's group is a key entity of the intermediate lesion between benign nevus and melanoma. The latest edition of the WHO Classification of Skin Tumours (2018) has excluded Clark nevus (dysplastic nevus of mild atypia) from dysplastic nevus, the latter being now classified into the low‐ and high‐grade by the degrees of nuclear atypia. The World Health Organization classification regards dysplastic nevus of both grades as the intermediate lesion between common acquired nevus and the radial growth‐phase melanoma. An extensive genetic study recently performed by Bastian's group indicated the existence of intermediate lesions between nevus and melanoma. In spite of these findings, some investigators doubt the concept of the intermediate lesions including dysplastic nevus and insist that the majority of melanomas arise de novo as melanoma in situ, not in association with a preceding nevus. The concept of de novo genesis of melanoma may be supported by a recent meta‐analysis study revealing that 71% of melanomas likely arose de novo and 29% from pre‐existing nevus. In this review article, from the viewpoint of de novo genesis of melanoma, the author critically discusses the relevant findings of melanoma genesis and proposes a new framework to interpret the morphological and genetic data alternatively. Clarification of the oncogenic process of melanoma has great impact not only on clinical dermatology but also on basic oncology.
- 1 February 2014
- Published by Wolters Kluwer Health in Melanoma Research
- Vol. 24 (1) , 83-87
Palmar and plantar melanomas differ for sex prevalence and tumor thickness but not for dermoscopic patterns
The specific anatomy of the glabrous skin, characterized by marked orthokeratosis and the presence of furrows and ridges, results in peculiar dermoscopic patterns of acral melanocytic lesions. Most frequently, acral nevi are typified by a parallel furrow pattern and acral melanoma (AM) by a parallel ridge pattern (PRP). Although the dermoscopic patterns of AM have been extensively investigated, little attention has been paid to site-related differences between palmar and plantar AM. The current study aimed to compare patients' characteristics, melanoma thickness, and the morphologic variability of AM depending on the localization on palms or soles. Patients demographics and dermoscopic images of 118 AM, including 99 (83.9%) plantar and 19 (16.1%) palmar lesions (mean thickness, 2.1 mm), were extracted from the databases of seven pigmented skin lesion clinics and were evaluated for the presence of predefined criteria. Palmar melanomas were remarkably more frequent in women (male-to-female ratio, 1/3.8) and thinner than plantar melanomas (1.3 vs. 2.2 mm). Dermoscopically, no significant differences were found between plantar and palmar melanomas, with PRP scored in 64.6 and 68.4% of plantar and palmar lesions, respectively. Non-site-specific melanoma criteria were detected in 83.9% of lesions and, among melanomas not exhibiting a PRP, 95.1% showed at least one non-site-specific melanoma criterion. In conclusion, plantar and palmar AMs show sex-related and thickness-related differences, but do not differ with respect to their dermoscopic features. For cases lacking the PRP, non-site-specific melanoma criteria may be considered as helpful additional clues for the correct diagnosis. © 2014 Wolters Kluwer Health | Lippincott Williams & Wilkins
- 1 February 2014
- Published by Wolters Kluwer Health in Melanoma Research
- Vol. 24 (1) , 83-87
Palmar and plantar melanomas differ for sex prevalence and tumor thickness but not for dermoscopic patterns
The specific anatomy of the glabrous skin, characterized by marked orthokeratosis and the presence of furrows and ridges, results in peculiar dermoscopic patterns of acral melanocytic lesions. Most frequently, acral nevi are typified by a parallel furrow pattern and acral melanoma (AM) by a parallel ridge pattern (PRP). Although the dermoscopic patterns of AM have been extensively investigated, little attention has been paid to site-related differences between palmar and plantar AM. The current study aimed to compare patients' characteristics, melanoma thickness, and the morphologic variability of AM depending on the localization on palms or soles. Patients demographics and dermoscopic images of 118 AM, including 99 (83.9%) plantar and 19 (16.1%) palmar lesions (mean thickness, 2.1 mm), were extracted from the databases of seven pigmented skin lesion clinics and were evaluated for the presence of predefined criteria. Palmar melanomas were remarkably more frequent in women (male-to-female ratio, 1/3.8) and thinner than plantar melanomas (1.3 vs. 2.2 mm). Dermoscopically, no significant differences were found between plantar and palmar melanomas, with PRP scored in 64.6 and 68.4% of plantar and palmar lesions, respectively. Non-site-specific melanoma criteria were detected in 83.9% of lesions and, among melanomas not exhibiting a PRP, 95.1% showed at least one non-site-specific melanoma criterion. In conclusion, plantar and palmar AMs show sex-related and thickness-related differences, but do not differ with respect to their dermoscopic features. For cases lacking the PRP, non-site-specific melanoma criteria may be considered as helpful additional clues for the correct diagnosis. © 2014 Wolters Kluwer Health | Lippincott Williams & Wilkins
- Open Access
- 26 April 2012
- Published by Springer Nature in International Journal of Clinical Oncology
- Vol. 18 (3) , 506-509
Platinum and anthracycline therapy for advanced cutaneous squamous cell carcinoma
Background Because metastatic cutaneous squamous cell carcinoma (CSCC) is rare, standard chemotherapy has not been fully established. In Japan, combination platinum and anthracycline chemotherapy has been used for elderly patients with advanced CSCC because of its low toxicity. However, the clinical benefit of this therapy has not been fully examined. Methods We retrospectively examined the response rate of combination platinum and anthracycline chemotherapy for metastatic CSCC. Results Eight patients received combination chemotherapy for metastatic lesions; there were lymph node lesions in 6 patients and skin and lung lesions in one patient each. The combination regimens were as follows: cisplatin (CDDP) (60–90 mg/m2/day, day 1) and adriamycin (ADM) (20–40 mg/m2/day, day 1 or 2) was administered in 5 patients; CDDP (10–15 mg/m2/day, days 1–5) and epirubicin (epi-ADM) (10–15 mg/m2/day, days 1–5) was administered in 2 patients; and carboplatin (CBDCA) (200–400 mg/m2/day, day 1) and ADM (20–40 mg/m2/day, day 1 or 2) was administered in one patient. The responses were as follows: complete response in 2 patients (CDDP + ADM for lung metastasis, CDDP + epi-ADM for lymph node metastasis), partial response in 1 (CDDP + ADM for lymph node metastasis), stable disease in 2, and progressive disease in 3. A durable response was observed in 2 patients showing complete responses (58 and 112 months). Conclusions The clinical effect of the combination of platinum and anthracycline for metastatic CSCC was limited despite the findings of two patients showing durable complete responses.
- 26 April 2012
- Published by Springer Nature in International Journal of Clinical Oncology
- Vol. 18 (3) , 506-509
Open AccessPlatinum and anthracycline therapy for advanced cutaneous squamous cell carcinoma
Background Because metastatic cutaneous squamous cell carcinoma (CSCC) is rare, standard chemotherapy has not been fully established. In Japan, combination platinum and anthracycline chemotherapy has been used for elderly patients with advanced CSCC because of its low toxicity. However, the clinical benefit of this therapy has not been fully examined. Methods We retrospectively examined the response rate of combination platinum and anthracycline chemotherapy for metastatic CSCC. Results Eight patients received combination chemotherapy for metastatic lesions; there were lymph node lesions in 6 patients and skin and lung lesions in one patient each. The combination regimens were as follows: cisplatin (CDDP) (60–90 mg/m2/day, day 1) and adriamycin (ADM) (20–40 mg/m2/day, day 1 or 2) was administered in 5 patients; CDDP (10–15 mg/m2/day, days 1–5) and epirubicin (epi-ADM) (10–15 mg/m2/day, days 1–5) was administered in 2 patients; and carboplatin (CBDCA) (200–400 mg/m2/day, day 1) and ADM (20–40 mg/m2/day, day 1 or 2) was administered in one patient. The responses were as follows: complete response in 2 patients (CDDP + ADM for lung metastasis, CDDP + epi-ADM for lymph node metastasis), partial response in 1 (CDDP + ADM for lymph node metastasis), stable disease in 2, and progressive disease in 3. A durable response was observed in 2 patients showing complete responses (58 and 112 months). Conclusions The clinical effect of the combination of platinum and anthracycline for metastatic CSCC was limited despite the findings of two patients showing durable complete responses.
- 1 April 2012
- Published by Wolters Kluwer Health in Dermatologic Surgery
- Vol. 38 (4) , 692-694
Surgical Treatment of Nail Apparatus Melanoma in situ: The Use of Artificial Dermis in Reconstruction
- 1 April 2012
- Published by Wolters Kluwer Health in Dermatologic Surgery
- Vol. 38 (4) , 692-694
Surgical Treatment of Nail Apparatus Melanoma in situ: The Use of Artificial Dermis in Reconstruction
- 1 July 2011
- Published by Wolters Kluwer Health in The American Journal of Dermatopathology
- Vol. 33 (5) , 468-473
Characteristic Distribution of Melanin Columns in the Cornified Layer of Acquired Acral Nevus: An Important Clue for Histopathologic Differentiation From Early Acral Melanoma
Clinical and histopathologic differentiation between early acral melanoma and acral nevus is often difficult. Dermoscopy is helpful in this differentiation. On dermoscopy, early acral melanoma shows the parallel ridge pattern showing band-like pigmentation on the ridges of the surface skin markings, whereas a representative dermoscopic pattern in acquired acral nevus is the parallel furrow pattern showing parallel linear pigmentation along the surface furrows. The parallel furrow pattern suggests that melanocytes of acral nevus preferentially proliferate in the crista profunda limitans, an epidermal rete ridge underlying the surface furrow. In the present study, however, we found that in 13 of 18 acquired acral nevi, proliferation of melanocytes were detected not only in the crista profunda limitans but also in the crista profunda intermedia (CPI), an epidermal rete ridge underlying the surface ridge. Very interestingly, Fontana-Masson staining of these acral nevi revealed that even when proliferation of melanocytes was prominent in the CPI, melanin granules in the cornified layer were observed as regular melanin columns situated under the surface furrows and were hardly detected under the surface ridges. These findings indicate that in acral nevus, melanin granules produced by melanocytes in the CPI are not transferred to the upper epidermis. Hence, we must be careful not to overdiagnose an acral melanocytic lesion in which an increased number of melanocytes are detected in the CPI. Even in such a case, if melanin granules in the cornified layer are detected as melanin columns regularly distributed under the surface furrows, the lesion is strongly suggested to be a benign acral nevus.
- 1 July 2011
- Published by Wolters Kluwer Health in The American Journal of Dermatopathology
- Vol. 33 (5) , 468-473
Characteristic Distribution of Melanin Columns in the Cornified Layer of Acquired Acral Nevus: An Important Clue for Histopathologic Differentiation From Early Acral Melanoma
Clinical and histopathologic differentiation between early acral melanoma and acral nevus is often difficult. Dermoscopy is helpful in this differentiation. On dermoscopy, early acral melanoma shows the parallel ridge pattern showing band-like pigmentation on the ridges of the surface skin markings, whereas a representative dermoscopic pattern in acquired acral nevus is the parallel furrow pattern showing parallel linear pigmentation along the surface furrows. The parallel furrow pattern suggests that melanocytes of acral nevus preferentially proliferate in the crista profunda limitans, an epidermal rete ridge underlying the surface furrow. In the present study, however, we found that in 13 of 18 acquired acral nevi, proliferation of melanocytes were detected not only in the crista profunda limitans but also in the crista profunda intermedia (CPI), an epidermal rete ridge underlying the surface ridge. Very interestingly, Fontana-Masson staining of these acral nevi revealed that even when proliferation of melanocytes was prominent in the CPI, melanin granules in the cornified layer were observed as regular melanin columns situated under the surface furrows and were hardly detected under the surface ridges. These findings indicate that in acral nevus, melanin granules produced by melanocytes in the CPI are not transferred to the upper epidermis. Hence, we must be careful not to overdiagnose an acral melanocytic lesion in which an increased number of melanocytes are detected in the CPI. Even in such a case, if melanin granules in the cornified layer are detected as melanin columns regularly distributed under the surface furrows, the lesion is strongly suggested to be a benign acral nevus.
- 1 January 2011
- Published by The Japanese Skin Cancer Society in Skin Cancer
- Vol. 26 (2) , 139-142
A case of advanced malignant melanoma responding to single-dose dacarbazine
- 1 January 2011
- Published by The Japanese Skin Cancer Society in Skin Cancer
- Vol. 26 (2) , 139-142
A case of advanced malignant melanoma responding to single-dose dacarbazine